Johnson & Johnson has introduced MONARCH QUEST 3, a software update for its MONARCH Platform that adds AI-assisted planning, navigation enhancements, 3D orientation and broader imaging compatibility for bronchoscopic lung nodule procedures.

Johnson & Johnson introduced its robotic bronchoscopy and AI navigation platform at Cleveland Clinic Abu Dhabi to improve early diagnostic accuracy for peripheral lung lesions.

Next-generation software solution includes new AI capabilities to advance the standard of care in total hip arthroplasty (THA) by automating image interpretation, consistently identifying landmarks, and increasing procedural efficiencies.

Johnson & Johnson and Memorial Hermann-Texas Medical Center evaluate the OTTAVA robotic system's performance in multi-quadrant surgical procedures and existing operating room infrastructures.

Johnson & Johnson showcases AI-driven imaging and mapping solutions at HRS 2026 to enhance electrophysiology procedures and treatment of cardiac arrhythmias.

The acquisition adds a clinical-stage prostate cancer therapy and a novel RIPTAC platform aimed at improving precision targeting and overcoming treatment resistance in solid tumors.

Johnson & Johnson terminated its Phase 2b trial for JNJ-5939 after an interim analysis showed the drug failed to meet high-bar efficacy standards for treatment.

Johnson & Johnson MedTech can create high-fidelity digital twins using NVIDIA Omniverse libraries and build applications that simulate how the system may perform in the operating room and inside a patient.

The new tissue-sparing system enables day-one post-op mobility, enhances joint visualization, and supports outpatient surgery as shoulder replacements grow 7.3% annually.

Johnson & Johnson introduces its first forward IVL platform with a distal emitter, delivering 120 shockwaves to safely treat calcified lesions in peripheral artery disease patients.